Literature DB >> 18817997

Sorafenib in advanced hepatocellular carcinoma - We have won a battle not the war.

Peter R Galle1.   

Abstract

Entities:  

Year:  2008        PMID： 18817997     DOI： 10.1016/j.jhep.2008.09.001

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  10 in total

1.  The STORM trial and beyond: narrowing the horizon of adjuvant sorafenib for postoperative hepatocellular carcinoma.

Authors:  Jian-Hong Zhong
Journal:  Tumour Biol       Date:  2015-11

2.  Current approach in the treatment of hepatocellular carcinoma.

Authors:  Luigi Rossi; Federica Zoratto; Anselmo Papa; Francesca Iodice; Marina Minozzi; Luigi Frati; Silverio Tomao
Journal:  World J Gastrointest Oncol       Date:  2010-09-15

Review 3.  Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.

Authors:  Linda S Steelman; William H Chappell; Stephen L Abrams; Ruth C Kempf; Jacquelyn Long; Piotr Laidler; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Franca Stivala; Maria C Mazzarino; Marco Donia; Paolo Fagone; Graziella Malaponte; Ferdinando Nicoletti; Massimo Libra; Michele Milella; Agostino Tafuri; Antonio Bonati; Jörg Bäsecke; Lucio Cocco; Camilla Evangelisti; Alberto M Martelli; Giuseppe Montalto; Melchiorre Cervello; James A McCubrey
Journal:  Aging (Albany NY)       Date:  2011-03       Impact factor: 5.682

Review 4.  Sorafenib: a review of its use in advanced hepatocellular carcinoma.

Authors:  Gillian M Keating; Armando Santoro
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 5.  Targeted therapy for hepatocellular carcinoma.

Authors:  Hans Christian Spangenberg; Robert Thimme; Hubert E Blum
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-06-02       Impact factor: 46.802

6.  Gene expression-based chemical genomics identifies potential therapeutic drugs in hepatocellular carcinoma.

Authors:  Ming-Huang Chen; Wu-Lung R Yang; Kuan-Ting Lin; Chia-Hung Liu; Yu-Wen Liu; Kai-Wen Huang; Peter Mu-Hsin Chang; Jin-Mei Lai; Chun-Nan Hsu; Kun-Mao Chao; Cheng-Yan Kao; Chi-Ying F Huang
Journal:  PLoS One       Date:  2011-11-07       Impact factor: 3.240

7.  Systemic metastasis of hepatocellular carcinoma responsive to multidisciplinary treatment including debulking surgery.

Authors:  Hwa-Kyung Jung; Dong-Shik Lee; Sung-Su Yoon; Hong-Jin Kim
Journal:  Ann Surg Treat Res       Date:  2014-01-22       Impact factor: 1.859

8.  Discovery of Coumarin as Microtubule Affinity-Regulating Kinase 4 Inhibitor That Sensitize Hepatocellular Carcinoma to Paclitaxel.

Authors:  Xianyan Shen; Xuesha Liu; Shunli Wan; Xin Fan; Huaiyu He; Rong Wei; Wenchen Pu; Yong Peng; Chun Wang
Journal:  Front Chem       Date:  2019-05-24       Impact factor: 5.221

9.  Swertiamarin suppresses proliferation, migration, and invasion of hepatocellular carcinoma cells <em>via</em> negative regulation of FRAT1.

Authors:  Shufeng Xiao; Haoren Tang; Yao Bai; Renchao Zou; Zongfang Ren; Xuesong Wu; Zhitian Shi; Song Lan; Wei Liu; Tiangen Wu; Cheng Zhang; Lin Wang
Journal:  Eur J Histochem       Date:  2020-10-19       Impact factor: 3.188

10.  Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma.

Authors:  Hsiang-Chi Tseng; Wei Xiong; Saiaditya Badeti; Yan Yang; Minh Ma; Ting Liu; Carlos A Ramos; Gianpietro Dotti; Luke Fritzky; Jie-Gen Jiang; Qing Yi; James Guarrera; Wei-Xing Zong; Chen Liu; Dongfang Liu
Journal:  Nat Commun       Date:  2020-09-23       Impact factor: 17.694
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.